Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis. Issue 7 (20th May 2019)

• Record Type: Journal Article
• Authors: Li, Juan; Li, Hang; Lv, Xiaoting; Yang, Zitai; Gao, Min; Bi, Yanhong; Zhang, Ziwei; Wang, Shengli; Cui, Zhigang; Zhou, Baosen; Yin, Zhihua
• Is Part Of: Molecular genetics & genomic medicine. Volume 7:Issue 7(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-05-20
• Subjects: biomarker -- cancer -- CircRNA -- diagnosis; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.749
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Background: Recently, accumulating evidence have revealed that circular RNA (circRNA) was deregulated in multiple types of cancer, suggesting that circRNA might serve as a novel candidate biomarker of cancer diagnosis. However, inconsistent results have become an obstacle in applying circRNAs to clinical practice. The aim of this study is to evaluate diagnostic value of circRNAs among cancers. Methods: A literature search was systematically performed among PubMed, Sciencedirect, Cochrane Library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases up to February 15, 2019. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratios, negative likelihood ratios, diagnostic odds ratio, and area under the SROC curve (AUC) were applied to evaluate diagnostic performance of circRNAs. Results: In total, the study included 64 studies with single circRNA and 13 studies with combined circRNAs. Overall, the study presented that a single circRNA had moderate diagnostic value, with a SEN of 0.75, a SPE of 0.76, and an AUC of 0.82. The plasma circRNAs had higher diagnostic accuracy than tissue (AUC: 0.87, 95% confidence interval [CI]: 0.83–0.89 for plasma/serum subgroup; AUC: 0.79, 95% CI: 0.75–0.82 for tissue subgroup). Furthermore, the combined circRNAs had good diagnostic efficacy for GC, with a SEN of 0.89, a SPE of 0.94, and an AUC of 0.97, respectively. Conclusion: This study confirmed that circRNAs may be candidate biomarkers for cancer diagnosis. In particular, diagnosis of combined circRNAs will be a new alternative applied to clinical research and practice for cancer. Abstract : Sensitivity (a), specificity (b), and SROC curve (e) were applied to evaluate diagnostic accuracy of combined circRNA. Fagan's nomogram (d) was constructed to calculate the post‐test probabilities for the clinical utility. The ROC plane (c) was conducted to examine the heterogeneity caused by threshold effect. A bivariate box plot (f) was used to evaluate the heterogeneity of each study. Deeks' funnel plot (g) asymmetry test was applied to examine publication bias.